DOI QR코드

DOI QR Code

Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

  • Altinbas, Mustafa (Medical Oncology Clinic, Diskapi Yildirim Beyazit Education and Research Hospital) ;
  • Kalender, Mehmet Emin (Medical Oncology Department, Gaziantep University) ;
  • Oven, Basak (Medical Oncology Clinic, Kartal Lutfu Kirdar Education and Research Hospital) ;
  • Sevinc, Alper (Medical Oncology Department, Gaziantep University) ;
  • Karaca, Halit (Medical Oncology Department, Erciyes University) ;
  • Kaplan, M. Ali (Medical Oncology Department, Dicle University) ;
  • Alici, Suleyman (Medical Oncology Unit) ;
  • Arpaci, Erkan (Medical Oncology Clinic, Demetevler Oncology Hospital) ;
  • Yildiz, Ramazan (Medical Oncology Department, Gazi University) ;
  • Uncu, Dogan (Medical Oncology Clinic, Numune Education and Research Hospital) ;
  • Camci, Celalettin (Medical Oncology Department, Gaziantep University) ;
  • Gumus, Mahmut (Medical Oncology Clinic, Kartal Lutfu Kirdar Education and Research Hospital)
  • Published : 2012.06.30

Abstract

Aim: To evaluate efficacy and tolerability of topotecan treatment for recurrent small cell lung carcinoma. Patients and Methods: A total of 62 patients were evaluated retrospectively. Statistical analysis was performed using GraphPad Instat (version 3.05). Results: DFifty five of patients (89%) were male and 7 (11%) were female. Median age was $56.7{\pm}9.3$ (34-75). Forty eight of patients (80%) were extensive stage (ES) at the time of diagnosis. Fifty of the patients (80.6 Medical Oncology Clinic) were given median 5.36 cycles of cisplatin-etoposide (2-8 cycles). Time to recurrence was $15.6{\pm}6.13$ weeks in patients with limited stage (LS) and $6.3{\pm}3.82$ weeks in extensive stage (ES) (p<0.0001). Overall survival was $14.0{\pm}6.08$ months in ES and $17.9{\pm}6.88$ months in LS. The difference between two groups was statistically meaningful (p=0.0447). The overall survival of the patients was $14.8{\pm}6.43$ months (4.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171). In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.

Keywords

Small cell lung cancer;recurrence;chemotherapy;topotecan;toxicity

References

  1. Ardizzoni A, Hansen H, Dombernowsky P, et al (1997). Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol, 15, 2090-6.
  2. Chua YJ, Ster C, Yip D (2004). Recent advances in management of small-cell lung cancer. Cancer Treat Rev, 30, 521-3. https://doi.org/10.1016/j.ctrv.2004.06.003
  3. Garst J, Buller R, Lane S, et al (2005). Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin Lung Cancer, 7, 190-6. https://doi.org/10.3816/CLC.2005.n.035
  4. Hoschek S, Hoschek-Risslegger U, Fiegl M, et al (2007). Das kleinzellige Bronchialkarzinom. Wien Klin Wochenschr, 119, 697-710. https://doi.org/10.1007/s00508-007-0913-1
  5. Huber RM, Gatzemeier U, Gross H, et al (2000). Topotecan in second-line treatment of small-cell lung cancer-reduced toxicity with individualized therapy. J Clin Oncol, 19, 546.
  6. Huisman C, Postmus PE, Giaccone G, et al (1999). Second-line chemotherapy and its evaluation in small-cell lung cancer. Cancer Treat Re, 25, 199-206. https://doi.org/10.1053/ctrv.1999.0125
  7. Janssen-Heijen ML, Coebergh JW. (2001). Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europa. Lung Cancer, 31, 123-37. https://doi.org/10.1016/S0169-5002(00)00197-5
  8. Murren J, Turrisi AT, Pass HI (2005). Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer. 7th ed. Philadelphia, Lippincott williams & Wilkins; 810-3.
  9. Niederle N, Deppermann KM, Wolf M (2008). Systemische therapie des kleinzelligen lungenkarzinoms. Induktions-, erhaltungs- und rezidivtherapie. Onkologe, 14, 1428-44.
  10. O'Brien MER, CuileanuTE, Tsekov H, et al (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol, 24, 5441-7. https://doi.org/10.1200/JCO.2006.06.5821
  11. Pawel J, Schiller JH, Shepahard FA, et al (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17, 658-67.
  12. Perez-Soler R, Glisson BS, Lee JS, et al (1996). Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol, 14, 2785.
  13. Ruckdeschel JC, Scwartz AG, Bepler G, et al (2004). Cancer of the lung. In: Abeloff MD, Armitage JO, Niederhuber JE, et al (eds). Clinical oncology. 3rd ed. Churchill livingstone, Elsevier; 1649-3.
  14. Sambrook RJ, Girling DJ (2001). A national survey of the chemotherapy regimens used to treat small lung cancer (SCLC) in the United Kingdom. Br J Cancer, 84, 1447-52 https://doi.org/10.1054/bjoc.2001.1817
  15. Ukena D, Huwer H, Dornhoff W (2008). Bronchialkarzinome. In: Preiss J, Dornhoff W, Hagman FG, Schmieder A (eds). Onkologie 2008/09. Munchen, W. Zuckschwerdt Verlag; 86-9.
  16. Wolf M, Tebbe S, Fink T (2004). First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer, 45, 223-4. https://doi.org/10.1016/j.lungcan.2004.07.971

Cited by

  1. in HepG2 Human Hepatoma Cells vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.963